The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Baricitinib Also Appears Effective in Biologic-Refractory RA

Baricitinib Also Appears Effective in Biologic-Refractory RA

February 21, 2018 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—The selective Janus kinase 1 and 2 inhibitor baricitinib appears also to help patients whose rheumatoid arthritis (RA) has not responded adequately to biologic disease-modifying antirheumatic drugs, according to results from the RA-BEACON randomized trial.

You Might Also Like
  • Baricitinib Appears Effective in Biologic-Refractory RA
  • Baricitinib Effective for Treating Refractory Rheumatoid Arthritis
  • Long-Term Data Show Baricitinib Is Safe & Effective for RA
Also By This Author
  • Higher Tocilizumab Dose Plus Methotrexate Best for Early RA

The previously published overall results from RA-BEACON showed that baricitinib-treated patients had significantly better functional and clinical responses at week 12 than placebo.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In the current study, Dr. Mark C. Genovese from Stanford University Medical Center, in Palo Alto, California, and colleagues undertook exploratory, post hoc analyses to evaluate the effect of prior use of biologic disease-modifying antirheumatic drugs (bDMARDs) on the efficacy and safety of baricitinib.

For the primary endpoint, a 20% improvement in American College of Rheumatology criteria (ACR20) at week 12, there were no significant interactions based on the patient’s prior experience by the number of prior dMARDS, the number of prior TNF inhibitors, the number of prior non-TNF inhibitor treatments, or specific prior TNF inhibitor, the team reports in Rheumatology, online February 3.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Similarly, when evaluating ACR20 responses at weeks 12 and 24 according to the patient’s last bDMARD before randomization, the researchers found that response rates for baricitinib were numerically higher than those for placebo regardless of which TNF inhibitor or non-TNF inhibitor was used, with the exception of baricitinib 2 mg versus infliximab.

There was no increase in serious infections for either baricitinib dose according to prior biologic use, including for patients who had received multiple prior biologics.

“Baricitinib demonstrated a consistent, beneficial treatment effect in bDMARD-refractory patients across subgroups based on baseline characteristics and prior bDMARD use,” the researchers conclude. “Because the population of rheumatoid arthritis patients who are TNF-inhibitor inadequate responders is increasing, this finding may be clinically relevant.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Genovese did not respond to a request for comment.

Eli Lilly & Co. and Incyte sponsored the trial. Eli Lilly employed half of the authors and had various relationships with several others.

Reference

  1. Genovese MC, Kremer JM, Kartman CE, et al. Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis. Rheumatology (Oxford). 2018 Feb 3. [Epub ahead of print]

 

Filed Under: Conditions, Drug Updates, Rheumatoid Arthritis Tagged With: (bDMARDs), American College of Rheumatology criteria (ACR20), baricitinib, biologic disease-modifying antirheumatic drugs, biologic-refractory RA, RA-BEACON, Rheumatoid Arthritis (RA)

You Might Also Like:
  • Baricitinib Appears Effective in Biologic-Refractory RA
  • Baricitinib Effective for Treating Refractory Rheumatoid Arthritis
  • Long-Term Data Show Baricitinib Is Safe & Effective for RA
  • Baricitinib Has Promising Clinical Trial Results for Treating RA

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)